|
|
|
|
|
|
|
|
|
|
Blogger's Note: this editorial references a breast cancer study/CTC
Circulating Tumor DNA — Ready for Prime Time? — NEJM
" In summary, the new study provides proof of the concept that circulating tumor DNA represents a sensitive biomarker of tumor burden. Demonstration that the method can be used to take better care of patients with metastatic breast or other cancers in a cost-effective manner awaits further studies, which are clearly warranted."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.